/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | ENGNenGene Therapeutics |
|---|---|
| Last close | $1.77close 2026-11-09 |
| Change % | +1.14%close 2026-11-09 |
| Market cap | $119Mclose 2026-11-09 |
| P/E | 0.8FY to 2025-10-31 |
| Revenue | no revenue filed |
| Rev growth (YoY) | no revenue filed |
| Net income | $-117302000⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2025-10-31 Filing10-K · 0001193125-25-328743 · filed 2025-12-22 Open the filing on EDGAR →Open the XBRL payload →CiteenGene Therapeutics Inc. (ENGN), us-gaap:NetIncomeLoss: -117,302,000 USD, fiscal year ended 2025-10-31. Form 10-K, accession 0001193125-25-328743, filed 2025-12-22. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001980845/us-gaap/NetIncomeLoss.json |
| Net margin | not filed |
| EPS (diluted) | $2.29⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldEarningsPerShareDiluted As ofFY ending 2025-10-31 Filing10-K · 0001193125-25-328743 · filed 2025-12-22 Open the filing on EDGAR →Open the XBRL payload →CiteenGene Therapeutics Inc. (ENGN), us-gaap:EarningsPerShareDiluted: 2.29 USD per share, fiscal year ended 2025-10-31. Form 10-K, accession 0001193125-25-328743, filed 2025-12-22. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001980845/us-gaap/EarningsPerShareDiluted.json |
| Piotroski F-ScoreUNVALIDATED | not scored |
| Altman Z-ScoreUNVALIDATED | not scored |
| Beneish M-ScoreUNVALIDATED | not scored |
| Next earnings | 12-16 → 12-26 |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.